BNP Paribas Financial Markets’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-37,810
| Closed | -$2.26M | – | 4563 |
|
|
2019
Q4 | $2.26M | Buy |
37,810
+30,981
| +454% | +$1.16M | ﹤0.01% | 1620 |
|
|
2019
Q3 | $192K | Buy |
6,829
+2,702
| +65% | +$92.2K | ﹤0.01% | 2775 |
|
|
2019
Q2 | $156K | Sell |
4,127
-3,603
| -47% | -$138K | ﹤0.01% | 2772 |
|
|
2019
Q1 | $302K | Buy |
7,730
+7,505
| +3,336% | +$215K | ﹤0.01% | 2444 |
|
|
2018
Q4 | $4.8K | Sell |
225
-1,047
| -82% | -$27K | ﹤0.01% | 3603 |
|
|
2018
Q3 | $50.4K | Hold |
1,272
| – | – | ﹤0.01% | 3036 |
|
|
2018
Q2 | $48.6K | Sell |
1,272
-2,758
| -68% | -$102K | ﹤0.01% | 3130 |
|
|
2018
Q1 | $121K | Buy |
4,030
+533
| +15% | +$18K | ﹤0.01% | 3095 |
|
|
2017
Q4 | $109K | Buy |
3,497
+2,154
| +160% | +$59.1K | ﹤0.01% | 3253 |
|
|
2017
Q3 | $37.6K | Sell |
1,343
-271
| -17% | -$5.88K | ﹤0.01% | 3294 |
|
|
2017
Q2 | $30.9K | Buy |
1,614
+1,350
| +511% | +$21.6K | ﹤0.01% | 3429 |
|
|
2017
Q1 | $4.5K | Buy |
264
+136
| +106% | +$2.2K | ﹤0.01% | 3342 |
|
|
2016
Q4 | $2.34K | Sell |
128
-78
| -38% | -$1.35K | ﹤0.01% | 3898 |
|
|
2016
Q3 | $3.67K | Buy |
+206
| New | +$3.13K | ﹤0.01% | 3428 |
|
BNP Paribas Financial Markets's BOLD Position: Q1 2020 in Review
BNP Paribas Financial Markets sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 37,810 shares — an estimated $2.26M sold.
BNP Paribas Financial Markets first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $2.26M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- BNP Paribas Financial Markets reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- BNP Paribas Financial Markets sold 37,810 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $2.26M.
- BNP Paribas Financial Markets first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- BNP Paribas Financial Markets's Audentes Therapeutics, Inc position peaked at $2.26M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on BNP Paribas Financial Markets's 13F filing for Q1 2020, filed 13 May 2020.